

ClinicalTrials.gov Search Results 08/11/2018

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
1	NCT03489278	Clinical Procedures to Support Research	Title Acronym: CAPTURE	Recruiting	<ul style="list-style-type: none">Amyotrophic Lateral SclerosisALS- Frontotemporal DementiaPrimary Lateral SclerosisProgressive Muscular Atrophy		Study Type: Observational	Enrollment: 1200	<ul style="list-style-type: none">University of MiamiMuscular Dystrophy AssociationNational Institute of Neurological Disorders and Stroke (NINDS)National Center for Advancing Translational Science (NCATS)National Institutes of Health (NIH)	<ul style="list-style-type: none">OtherNIH	Study Start: February 15, 2018	<ul style="list-style-type: none">California Pacific Medical Center, San Francisco, California, United StatesUniversity of Miami, Miami, Florida, United States
		Study Documents:	Other Ids: <ul style="list-style-type: none">20170785U54NS092091				Phase:	Age: 18 Years and older (Adult, Older Adult)			Primary Completion: January 2021	
							Study Design: <ul style="list-style-type: none">Observational Model: CohortTime Perspective: Prospective	Sex: All			Study Completion: January 2021	
							Outcome Measures: Using the ALS Toolkit for collecting and using electronic health record data for research purposes				First Posted: April 5, 2018	
											Results First Posted: No Results Posted	
											Last Update Posted: April 5, 2018	
2	NCT03196375	A Study to Assess FLX-787 in Subjects With Motor Neuron Disease Experiencing Muscle Cramps.	Title Acronym:	Active, not recruiting	<ul style="list-style-type: none">Motor Neuron Disease	<ul style="list-style-type: none">Drug: FLX-787-ODT (orally disintegrating tablet)Drug: Placebo ODT	Study Type: Interventional	Enrollment: 120	<ul style="list-style-type: none">Flex Pharma, Inc.	<ul style="list-style-type: none">Industry	Study Start: July 28, 2017	<ul style="list-style-type: none">Honor Health Research Institute, Scottsdale, Arizona, United StatesMayo Clinic, Scottsdale, Arizona, United StatesCalifornia Pacific Medical Center, Sacramento, California, United StatesUniversity of California - Davis, Sacramento, California, United StatesUniversity of California San Francisco, San Francisco, California, United StatesUniversity of Colorado, Aurora, Colorado, United StatesHospital for Special Care, New Britain, Connecticut, United StatesGW Medical Faculty Associates Inc., Washington, District of Columbia, United StatesMayo Clinic, Jacksonville, Florida, United StatesUniversity of South Florida Health, Tampa, Florida, United Statesand 25 more
		Study Documents:	Other Ids: FLX-787-203				Phase: Phase 2	Age: 18 Years and older (Adult, Older Adult)			Primary Completion: June 2018	
							Study Design: <ul style="list-style-type: none">Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)Primary Purpose: Treatment	Sex: All			Study Completion: June 2018	
							Outcome Measures: Cramp frequency				First Posted: June 22, 2017	
											Results First Posted: No Results Posted	
											Last Update Posted: June 14, 2018	

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
3	NCT02868567	<div>Use of Dalfampridin in Primary Lateral Sclerosis</div> <div>Study Documents:</div>	<div>Title Acronym:</div> <div>Other Ids: 2016-247</div>	Recruiting	•Motor Neuron Disease, Upper	•Drug: dalfampridine	<div>Study Type: Interventional</div> <div>Phase: Phase 1</div> <div>Study Design: •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Treatment</div> <div>Outcome Measures: •consistent improvement in the Timed 25 Foot Walk test •Effect of Dalfampridine on quality of life •Effects of Dalfampridine on functional status</div>	<div>Enrollment: 35</div> <div>Age: 18 Years to 99 Years (Adult, Older Adult)</div> <div>Sex: All</div>	•Weill Medical College of Cornell University •Hospital for Special Surgery, New York	•Other	<div>Study Start: March 2016</div> <div>Primary Completion: January 2019</div> <div>Study Completion: January 2019</div> <div>First Posted: August 16, 2016</div> <div>Results First Posted: No Results Posted</div> <div>Last Update Posted: January 9, 2018</div>	•Hospital for Special Surgery, New York, New York, United States
4	NCT02795897	<div>Genomic Translation for ALS Care</div> <div>Study Documents:</div>	<div>Title Acronym: GTAC</div> <div>Other Ids: AAAQ7026</div>	Recruiting	•ALS		<div>Study Type: Observational</div> <div>Phase:</div> <div>Study Design: •Observational Model: Cohort •Time Perspective: Prospective</div> <div>Outcome Measures: •Correlation of DNA genotype with ALS phenotypes •Correlation of gene expression in blood with ALS phenotypes</div>	<div>Enrollment: 1500</div> <div>Age: 18 Years to 80 Years (Adult, Older Adult)</div> <div>Sex: All</div>	•Columbia University •ALS Association •Biogen	•Other •Industry	<div>Study Start: November 2016</div> <div>Primary Completion: June 2019</div> <div>Study Completion: November 2020</div> <div>First Posted: June 10, 2016</div> <div>Results First Posted: No Results Posted</div> <div>Last Update Posted: June 8, 2018</div>	•Cedar Sinai Medical Center, Los Angeles, California, United States •Univeristy of Michigan, Ann Arbor, Michigan, United States •University of Minnesota, Minneapolis, Minnesota, United States •Washington University, Saint Louis, Missouri, United States •Columbia University, New York, New York, United States •Duke University, Durham, North Carolina, United States •Oregon Health & Sciences University, Portland, Oregon, United States •Penn State College of Medicine, Hershey, Pennsylvania, United States •University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States •Houston Methodist Neurological Institute, Houston, Texas, United States •and 3 more

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
5	NCT02574390	Answer ALS: Individualized Initiative for ALS Discovery	Title Acronym: AnswerALS	Recruiting	<ul style="list-style-type: none">•Amyotrophic Lateral Sclerosis•Primary Lateral Sclerosis•Flail Arm ALS•Progressive Muscular Atrophy•Monomelic Amyotrophy•Motor Neuron Disease•Asymptomatic ALS Gene Carriers•Healthy Controls		Study Type: Observational	Enrollment: 1000	<ul style="list-style-type: none">•Johns Hopkins University•Massachusetts General Hospital•Emory University•Ohio State University•Washington University School of Medicine•Cedars-Sinai Medical Center•University of California, Irvine•Massachusetts Institute of Technology•New York Genome Center•Leandro P. Rizzuto Foundation•Texas Neurology•Northwestern University Les Turner ALS Center	•Other	Study Start: December 2015	<ul style="list-style-type: none">•Cedars-Sinai Medical Center, Los Angeles, California, United States•Emory University, Atlanta, Georgia, United States•Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States•Johns Hopkins University, Baltimore, Maryland, United States•Massachusetts General Hospital, Boston, Massachusetts, United States•Washington University School of Medicine, Saint Louis, Missouri, United States•Ohio State University Wexner Medical Center, Columbus, Ohio, United States•Texas Neurology, Dallas, Texas, United States
		Study Documents:	Other Ids: IRB00082277				Phase:	Age: 18 Years to 100 Years (Adult, Older Adult)			Primary Completion: January 2019	
6	NCT02567136	Imaging Biomarkers in ALS	Title Acronym:	Active, not recruiting	<ul style="list-style-type: none">•Amyotrophic Lateral Sclerosis•Primary Lateral Sclerosis		Study Type: Observational	Enrollment: 30	<ul style="list-style-type: none">•University of Minnesota - Clinical and Translational Science Institute	•Other	Study Start: September 2015	<ul style="list-style-type: none">•University of Minnesota, Minneapolis, Minnesota, United States
		Study Documents:	Other Ids: 130126				Phase:	Age: 21 Years to 75 Years (Adult, Older Adult)			Primary Completion: September 2025	
							Study Design: <ul style="list-style-type: none">•Observational Model: Case-Control•Time Perspective: Prospective	Sex: All			Study Completion: September 2025	
							Outcome Measures: Imaging biomarkers				First Posted: October 2, 2015	
											Results First Posted: No Results Posted	
											Last Update Posted: May 7, 2018	

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
7	NCT02408900	<div><div>Muscle Ultrasound Measures as Biomarkers of Upper Motor Neuron Function</div><div>Study Documents:</div></div>	<div>Title Acronym:</div> <div>Other Ids:<ul style="list-style-type: none">•150106•15-N-0106</div>	Completed	•Muscle Spasticity		<div>Study Type: Observational</div> <div>Phase:</div> <div>Study Design:<ul style="list-style-type: none">•Observational Model: Cohort•Time Perspective: Cross-Sectional</div> <div>Outcome Measures:<ul style="list-style-type: none">•The primary outcome will be measuring muscle stiffness from the biceps brachii using ultrasound elastography, which will be compared between patient groups and control groups.•A secondary outcome will be the correlation of muscle stiffness at rest with the modified Ashworth score for elbow flexion.</div>	<div>Enrollment: 15</div> <div>Age: 18 Years to 75 Years (Adult, Older Adult)</div> <div>Sex: All</div>	<ul style="list-style-type: none">•National Institute of Neurological Disorders and Stroke (NINDS)•National Institutes of Health Clinical Center (CC)	•NIH	<div>Study Start: March 25, 2015</div> <div>Primary Completion: August 3, 2015</div> <div>Study Completion: August 3, 2015</div> <div>First Posted: April 6, 2015</div> <div>Results First Posted: No Results Posted</div> <div>Last Update Posted: August 7, 2018</div>	•National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
8	NCT02327845	<div><div>Phenotype, Genotype & Biomarkers in ALS and Related Disorders</div><div>Study Documents:</div></div>	<div>Title Acronym:</div> <div>Other Ids: U54NS092091</div>	Recruiting	<ul style="list-style-type: none">•Amyotrophic Lateral Sclerosis•Frontotemporal Dementia•Primary Lateral Sclerosis•Hereditary Spastic Paraplegia•Progressive Muscular Atrophy•Multisystem Proteinopathy		<div>Study Type: Observational</div> <div>Phase:</div> <div>Study Design:<ul style="list-style-type: none">•Observational Model: Cohort•Time Perspective: Prospective</div> <div>Outcome Measures:<ul style="list-style-type: none">•Phenotypic correlates of genotype•Genetic determinants of phenotype</div>	<div>Enrollment: 700</div> <div>Age: Child, Adult, Older Adult</div> <div>Sex: All</div>	<ul style="list-style-type: none">•University of Miami•National Institute of Neurological Disorders and Stroke (NINDS)•National Center for Advancing Translational Science (NCATS)•St. Jude Children's Research Hospital•ALS Association	•Other •NIH	<div>Study Start: April 2015</div> <div>Primary Completion: August 2019</div> <div>Study Completion: August 2019</div> <div>First Posted: December 30, 2014</div> <div>Results First Posted: No Results Posted</div> <div>Last Update Posted: January 23, 2018</div>	<ul style="list-style-type: none">•Stanford University, Palo Alto, California, United States•University of California San Diego (UCSD), San Diego, California, United States•California Pacific Medical Center (CPMC), San Francisco, California, United States•University of Miami, Miami, Florida, United States•University of Iowa, Iowa City, Iowa, United States•Kansas University Medical Center (KUMC), Kansas City, Kansas, United States•Twin Cities ALS Research Consortium, Minneapolis, Minnesota, United States•Wake Forest University, Winston-Salem, North Carolina, United States•Cleveland Clinic, Cleveland, Ohio, United States•University of Pennsylvania, Philadelphia, Pennsylvania, United States•and 6 more

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
9	NCT01143428	Oxidative Stress in Motor Neuron Disease: COSMOS Add-On Study	Title Acronym:	Completed	•Motor Neuron Disease •Primary Lateral Sclerosis		Study Type: Observational	Enrollment: 10	•National Institute of Neurological Disorders and Stroke (NINDS) •National Institutes of Health Clinical Center (CC)	•NIH	Study Start: May 13, 2010	•National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
			Other Ids: •100121				Phase:	Age: 20 Years and older (Adult, Older Adult)			Primary Completion:	
		Study Documents:	•10-N-0121				Study Design: Time Perspective: Other				Study Completion: August 3, 2015	
							Outcome Measures: Decline in ALSFRS score	Sex: All			First Posted: June 14, 2010	
											Results First Posted: No Results Posted	
10	NCT00821132	Genetics of Familial and Sporadic ALS	Title Acronym: ALS	Recruiting	•Amyotrophic Lateral Sclerosis (ALS) •Familial Amyotrophic Lateral Sclerosis •Amyotrophic Lateral Sclerosis With Frontotemporal Dementia •Lou Gehrig's Disease •Motor Neuron Disease •Primary Lateral Sclerosis	•Other: Genetic study of ALS families	Study Type: Observational	Enrollment: 15000	•Northwestern University	•Other	Study Start: January 1991	•Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
			Other Ids: •Lab01				Phase:	Age: 18 Years and older (Adult, Older Adult)			Primary Completion: December 2019	
		Study Documents:	•RO1N505641-04				Study Design: •Observational Model: Family-Based •Time Perspective: Other				Study Completion: December 2022	
							Outcome Measures: Identification of genes that increase risk for sporadic ALS or cause inherited ALS.	Sex: All			First Posted: January 13, 2009	
											Results First Posted: No Results Posted	
											Last Update Posted: March 29, 2018	

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
11	NCT00677768	<div><div>Validation of Biomarkers in Amyotrophic Lateral Sclerosis (ALS)</div><div>Study Documents:</div></div>	<div><div>Title Acronym: BIO_ALS-01</div><div>Other Ids: •BIO_ALS-01 •5RC1NS068179-02</div></div>	Completed	<div>•Amyotrophic Lateral Sclerosis</div> <div>•Lou Gehrig's Disease</div> <div>•Primary Lateral Sclerosis</div> <div>•Nervous System Diseases</div> <div>•Hereditary Spastic Paraparesis</div>	•Other: No intervention	<div>Study Type: Observational</div> <div>Phase:</div> <div>Study Design: •Observational Model: Case Control</div> <div>•Time Perspective: Prospective</div> <div>Outcome Measures: ALS Functional Rating Scale (ALSFRS-R)</div>	<div>Enrollment: 475</div> <div>Age: 30 Years to 80 Years (Adult, Older Adult)</div> <div>Sex: All</div>	<div>•Massachusetts General Hospital</div> <div>•ALS Association</div> <div>•ALS Therapy Alliance</div> <div>•National Institutes of Health (NIH)</div> <div>•National Institute of Neurological Disorders and Stroke (NINDS)</div>	•Other •NIH	<div>Study Start: April 2008</div> <div>Primary Completion: November 2015</div> <div>Study Completion: November 2015</div> <div>First Posted: May 14, 2008</div> <div>Results First Posted: No Results Posted</div> <div>Last Update Posted: June 3, 2016</div>	<div>•Phoenix Neurological Associates, Ltd., Phoenix, Arizona, United States</div> <div>•University of California Irvine, Orange, California, United States</div> <div>•Mayo Clinic Neurology, Jacksonville, Florida, United States</div> <div>•University of Miami, Miami, Florida, United States</div> <div>•Emory University, Atlanta, Georgia, United States</div> <div>•University of Chicago, Chicago, Illinois, United States</div> <div>•Johns Hopkins University, Baltimore, Maryland, United States</div> <div>•Massachusetts General Hospital, Boston, Massachusetts, United States</div> <div>•Lahey Clinic, Burlington, Massachusetts, United States</div> <div>•Saint Mary's Healthcare, Grand Rapids, Michigan, United States</div> <div>•and 20 more</div>
12	NCT00362362	<div><div>Collection of Blood Samples for DNA in Motor Neuron Disease</div><div>Study Documents:</div></div>	<div><div>Title Acronym:</div><div>Other Ids: •060224 •06-N-0224</div></div>	Completed	•Motor Neuron Diseases		<div>Study Type: Observational</div> <div>Phase:</div> <div>Study Design:</div> <div>Outcome Measures:</div>	<div>Enrollment: 23</div> <div>Age: 18 Years and older (Adult, Older Adult)</div> <div>Sex: All</div>	<div>•National Institute of Neurological Disorders and Stroke (NINDS)</div> <div>•National Institutes of Health Clinical Center (CC)</div>	•NIH	<div>Study Start: August 7, 2006</div> <div>Primary Completion:</div> <div>Study Completion: September 9, 2013</div> <div>First Posted: August 10, 2006</div> <div>Results First Posted: No Results Posted</div> <div>Last Update Posted: October 6, 2017</div>	•National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
13	NCT00334516	Brain Function in Primary Lateral Sclerosis and Amyotrophic Lateral Sclerosis	Title Acronym:	Completed	•Cerebral Cortex Dysfunction		Study Type: Observational	Enrollment: 77	•National Institute of Neurological Disorders and Stroke (NINDS) •National Institutes of Health Clinical Center (CC)	•NIH	Study Start: June 6, 2006	•National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
			Other Ids: •060174				Phase:	Age: 18 Years and older (Adult, Older Adult)			Primary Completion:	
		Study Documents:	•06-N-0174				Study Design:				Study Completion: August 3, 2015	
							Outcome Measures:	Sex: All			First Posted: June 8, 2006	
											Results First Posted: No Results Posted	
14	NCT00324454	Levetiracetam for Cramps, Spasticity and Neuroprotection in Motor Neuron Disease	Title Acronym:	Completed	•Motor Neuron Disease •Amyotrophic Lateral Sclerosis •Primary Lateral Sclerosis •Progressive Muscular Atrophy	•Biological: Levetiracetam	Study Type: Interventional	Enrollment: 20	•Duke University •UCB Pharma	•Other •Industry	Study Start: May 2006	•Duke University ALS Clinic - 932 Morreene Road, Durham, North Carolina, United States
			Other Ids: •Pro00005846				Phase: Phase 2	Age: 18 Years and older (Adult, Older Adult)			Primary Completion: December 2007	
		Study Documents:	•8380-06-3R0				Study Design: •Allocation: Non-Randomized •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Treatment	Sex: All			Study Completion: June 2008	
							Outcome Measures: •Safety and tolerability at 9 months of treatment. •Cramps scores, spasticity scores, FVC, ALSFRS, MMT				First Posted: May 11, 2006	
											Results First Posted: No Results Posted	
15	NCT00071435	Brain Function in Primary Lateral Sclerosis	Title Acronym:	Completed	•Motor Neuron Disease		Study Type: Observational	Enrollment: 36	•National Institute of Neurological Disorders and Stroke (NINDS) •National Institutes of Health Clinical Center (CC)	•NIH	Study Start: October 2003	•National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, Maryland, United States
			Other Ids: •040017				Phase:	Age: Child, Adult, Older Adult			Primary Completion:	
		Study Documents:	•04-N-0017				Study Design:				Study Completion: February 2006	
							Outcome Measures:	Sex: All			First Posted: October 23, 2003	
											Results First Posted: No Results Posted	
											Last Update Posted: March 4, 2008	

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
16	NCT00023075	Nuclear Magnetic Spectroscopy Imaging to Evaluate Primary Lateral Sclerosis, Hereditary Spastic Paraplegia and Amyotrophic Lateral Sclerosis <div>Study Documents:</div>	Title Acronym: <div>Other Ids:<ul style="list-style-type: none">•010241•01-N-0241</div>	Completed	<ul style="list-style-type: none">•Primary Lateral Sclerosis•Hereditary Spastic Paraplegia•Amyotrophic Lateral Sclerosis		Study Type: <div>Observational</div> Phase: <div>Study Design:</div> Outcome Measures:	Enrollment: <div>55</div> Age: <div>Child, Adult, Older Adult</div> Sex: <div>All</div>	<ul style="list-style-type: none">•National Institute of Neurological Disorders and Stroke (NINDS)•National Institutes of Health Clinical Center (CC)	•NIH	Study Start: <div>August 2001</div> Primary Completion: <div>Study Completion:<div>August 2003</div></div> First Posted: <div>August 23, 2001</div> Results First Posted: <div>No Results Posted</div> Last Update Posted: <div>March 4, 2008</div>	<ul style="list-style-type: none">•National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, Maryland, United States
17	NCT00015444	Screening and Natural History: Primary Lateral Sclerosis and Related Disorders <div>Study Documents:</div>	Title Acronym: <div>Other Ids:<ul style="list-style-type: none">•010145•01-N-0145</div>	Active, not recruiting	<ul style="list-style-type: none">•Primary Lateral Sclerosis		Study Type: <div>Observational</div> Phase: <div>Study Design:<ul style="list-style-type: none">•Observational Model: Cohort•Time Perspective: OtherOutcome Measures:<div>The primary outcome of this protocol is to document the natural history of clinical progression in PLS, defined as the change in clinical measures of movement speed over time: finger tapping, timed gait, and time to read a standard passage.</div></div>	Enrollment: <div>189</div> Age: <div>18 Years and older (Adult, Older Adult)</div> Sex: <div>All</div>	<ul style="list-style-type: none">•National Institute of Neurological Disorders and Stroke (NINDS)•National Institutes of Health Clinical Center (CC)	•NIH	Study Start: <div>May 1, 2001</div> Primary Completion: <div>Study Completion:</div> First Posted: <div>April 19, 2001</div> Results First Posted: <div>No Results Posted</div> Last Update Posted: <div>August 9, 2018</div>	<ul style="list-style-type: none">•National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
18	NCT00014976	Physiologic Studies of Spasticity <div>Study Documents:</div>	Title Acronym: <div>Other Ids:<ul style="list-style-type: none">•010148•01-N-0148</div>	Completed	<ul style="list-style-type: none">•Muscle Spasticity•Healthy		Study Type: <div>Observational</div> Phase: <div>Study Design:</div> Outcome Measures:	Enrollment: <div>48</div> Age: <div>21 Years to 80 Years (Adult, Older Adult)</div> Sex: <div>All</div>	<ul style="list-style-type: none">•National Institute of Neurological Disorders and Stroke (NINDS)•National Institutes of Health Clinical Center (CC)	•NIH	Study Start: <div>April 13, 2001</div> Primary Completion: <div>Study Completion:<div>November 1, 2010</div></div> First Posted: <div>April 18, 2001</div> Results First Posted: <div>No Results Posted</div> Last Update Posted: <div>July 2, 2017</div>	<ul style="list-style-type: none">•National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States